Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia
Status:
Terminated
Trial end date:
2021-04-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety of MEN1112, given as intravenous infusion,
in patients with relapsed or refractory AML. Pharmacokinetics, clinical activity and
potential immunogenicity of MEN1112 will be evaluated as well.